Granules Pharma gets USFDA EIR for Chantilly facility

Granules India Limited announced that its wholly-owned subsidiary, Granules Pharmaceuticals, Inc. (GPI), has received the Establishment Inspection Report (EIR) from the US FDA for its Chantilly, Virginia facility. The facility received a Voluntary Action Indicated (VAI) classification following an inspection conducted from March 30 to April 3, 2026, where four Form 483 observations were issued. This facility is crucial to Granules' global manufacturing and supply network, with a focus on quality and regulatory compliance.